Newron Pharmaceuticals

An investor group subscribed to 433,070 new shares, providing Newron with €5.5 million gross. The shares are to be traded on SIX from Tuesday. The financing is part of a package of up to €38 million to continue the phase‑III development of Evenamide; a further €5.5 million is to follow by the end of November and an additional €12 million is linked to positive phase‑III results. With the funds, Newron intends to advance the development of Evenamide as an adjunct therapy for treatment‑resistant schizophrenia and to secure funding beyond the pivotal 12‑week data. » More on finanzen.net

An investor group has subscribed for a second tranche of 433,070 newly issued Newron shares at EUR 19.24 per share, representing gross proceeds of EUR 5.5 million. The subscription is part of a total financing package of up to EUR 38 million to continue the global ENIGMA‑TRS phase‑3 program for Evenamide in treatment‑resistant schizophrenia. A third tranche of EUR 5.5 million is planned no later than 30 November 2026, and further shares worth EUR 12 million are to be subscribed if pivotal study results are positive. The new shares will trade under the same ISIN and be listed on SIX, the primary market in Düsseldorf, and the Xetra Quotation Board. » More on de.investing.com

Newron has completed screening for the potentially registration‑enabling phase‑3 study ENIGMA‑TRS 1 with Evenamide and expects to reach the required minimum of 600 randomized patients around mid‑October. To date, 996 patients have been screened, 411 have already been treated and 352 are still in screening; at least 200 additional patients are expected to be randomized. Newron expects first topline results from the 12‑week treatment phase in the first quarter of 2027. » More on de.investing.com